Related Experiment Video
Updated: Jan 4, 2026

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis
Published on: March 19, 2019
Glycobiology of Human Fungal Pathogens: New Avenues for Drug Development
Danielle J Lee1, Holly O'Donnell2, Françoise H Routier3
1Institute for Glycomics, Griffith University, Gold Coast Campus, Queensland, 4222, Australia; Member of Fraunhofer International Consortium for Anti-Infective Research (iCAIR), Nikolai-Fuchs Strasse 1, 30625 Hannover, Germany. danielle.lee2@griffithuni.edu.au.
Abstract:
Invasive fungal infections (IFI) are an increasing threat to the developing world, with fungal spores being ubiquitous and inhaled every day. Some fungal species are commensal organisms that are part of the normal human microbiota, and, as such, do not pose a threat to the immune system. However, when the natural balance of this association is disturbed or the host's immune system is compromised, these fungal pathogens overtake the organism, and cause IFI. To understand the invasiveness of these pathogens and to address the growing problem of IFI, it is essential to identify the cellular processes of the invading organism and their virulence. In this review, we will discuss the prevalence and current options available to treat IFI, including recent reports of drug resistance. Nevertheless, the main focus of this review is to describe the glycobiology of human fungal pathogens and how various components of the fungal cell wall, particularly cell wall polysaccharides and glycoconjugates, are involved in fungal pathogenicity, their biosynthesis and how they can be potentially exploited to develop novel antifungal treatment options. We will specifically describe the nucleotide sugar transporters (NSTs) that are important in fungal survival and suggest that the inhibition of fungal NSTs may potentially be useful to prevent the establishment of fungal infections.
Insights
Invasive fungal infections (IFI) are a growing threat. Targeting fungal cell wall glycobiology, specifically nucleotide sugar transporters (NSTs), offers a promising strategy for developing novel antifungal treatments and combating drug resistance.
Area of Science:
- Medical Mycology
- Molecular Biology
- Glycobiology
Background:
- Invasive fungal infections (IFI) pose a significant global health challenge, exacerbated by compromised immune systems and increasing drug resistance.
- Fungal spores are ubiquitous, and opportunistic pathogens can cause disease when host defenses are weakened or the normal microbiota is disrupted.
Purpose of the Study:
- To review the prevalence and treatment options for IFIs, with a focus on antifungal drug resistance.
- To elucidate the role of fungal glycobiology, particularly cell wall components, in pathogenicity.
- To explore nucleotide sugar transporters (NSTs) as potential targets for novel antifungal therapies.
Main Methods:
- Literature review of current IFI prevalence, treatments, and drug resistance.
- Analysis of fungal cell wall glycobiology, including polysaccharide and glycoconjugate biosynthesis.
- Examination of the function and potential inhibition of nucleotide sugar transporters (NSTs) in fungal pathogens.
Main Results:
- Fungal cell wall polysaccharides and glycoconjugates are critical for pathogenicity.
- Nucleotide sugar transporters (NSTs) play a vital role in fungal survival and virulence.
- Existing antifungal treatments face challenges due to emerging drug resistance.
Conclusions:
- Understanding fungal glycobiology is key to developing effective IFI treatments.
- Inhibiting fungal NSTs presents a promising avenue for novel antifungal drug development.
- Targeting specific molecular pathways, like NSTs, may overcome current antifungal resistance issues.
Related Concept Videos
Fungal Phylum Microsporidia
Fungal Group Zygomycota
Protein Glycosylation
Glycosylation occurs in...
Overview of Fungi

